XML 42 R56.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment and Geographical Data (Tables)
 12 Months Ended
Dec. 27, 2019
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information by Business Segment
Selected information by business segment was as follows:

Fiscal Year

2019
 
2018
 
2017
Net sales:
 
 
 
 
 
Specialty Brands
$
2,423.8

 
$
2,496.7

 
$
2,352.0

Specialty Generics
738.7

 
718.9

 
869.6

Net sales
3,162.5

 
3,215.6

 
3,221.6

Operating (loss) income:
 
 
 
 
 
Specialty Brands
$
1,174.5

 
$
1,093.1

 
$
1,146.3

Specialty Generics
108.1

 
89.3

 
266.4

Segment operating income
1,282.6

 
1,182.4

 
1,412.7

Unallocated amounts:
 
 
 
 
 
Corporate and unallocated expenses (1)          
(137.8
)
 
(155.8
)
 
(125.2
)
Intangible asset amortization
(853.4
)
 
(740.2
)
 
(694.5
)
Restructuring and related charges, net (2)
1.7

 
(108.2
)
 
(36.4
)
Non-restructuring impairment charges
(388.0
)
 
(3,893.1
)
 
(63.7
)
Separation costs (3)
(63.9
)
 
(6.0
)
 
—

R&D upfront payment (4)
(20.0
)
 
—

 
—

Opioid-related litigation settlement charge (5)
(1,643.4
)
 
—

 
—

Operating (loss) income
$
(1,822.2
)
 
$
(3,720.9
)
 
$
492.9

 
 
 
 
 
 
Depreciation and amortization:
 
 
 
 
 
Specialty Brands
$
862.4

 
$
762.5

 
$
712.0

Specialty Generics
88.7

 
89.6

 
96.3

 
$
951.1

 
$
852.1

 
$
808.3


(1)
Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.
(2)
Includes restructuring-related accelerated depreciation.
(3)
Represents costs incurred related to the separation of the Company's Specialty Generics segment, inclusive of costs related to the suspended spin-off of that business and rebranding costs associated with the Specialty Brands ongoing transformation, all of which are included in SG&A.
(4)
Represents R&D expense incurred related to an upfront payment made to Silence in connection with the license and collaboration agreement entered into in July 2019. See Note 6 for further information.
(5)
Subsequent to December 27, 2019, the Company announced an agreement in principle on the terms of a global settlement of all opioid-related claims against the Company and its subsidiaries. See Note 24 for further information.

 [1],[2]
Schedule of Net Sales from External Customers by Products
Net sales by product family within the Company's reportable segments were as follows:
 
Fiscal Year
 
2019
 
2018
 
2017
Acthar Gel
$
952.7

 
$
1,110.1

 
$
1,195.1

INOmax
571.4

 
542.7

 
505.2

Ofirmev
384.0

 
341.9

 
302.5

Therakos
246.9

 
231.2

 
214.9

Amitiza (1)
208.5

 
183.8

 
—

BioVectra (2)
40.1

 
53.1

 
54.7

Other
20.2

 
33.9

 
79.6

Specialty Brands
2,423.8

 
2,496.7

 
2,352.0

 
 
 
 
 
 
Hydrocodone (API) ad hydrocodone-containing tablets
76.3

 
65.9

 
85.3

Oxycodone (API) and oxycodone-containing tablets
74.9

 
66.1

 
88.0

Acetaminophen (API)
189.9

 
192.7

 
185.5

Other controlled substances
352.5

 
343.8

 
412.0

Other
45.1

 
50.4

 
98.8

Specialty Generics
738.7

 
718.9

 
869.6

Net Sales
$
3,162.5

 
$
3,215.6

 
$
3,221.6

(1)
Amitiza net sales consist of both product and royalty net sales. Refer to Note 4 for further details on Amitiza's revenues.
(2)
In November 2019, the Company completed the sale of BioVectra. Refer to Note 5 for further details.

 [3]
Schedule of Net Sales and Long-Lived Assets by Geographical Area
Selected information by geographic area was as follows:
 
Fiscal Year
 
2019
 
2018
 
2017
Net sales (1):
 
 
 
 
 
U.S.
$
2,765.6

 
$
2,834.5

 
$
2,899.0

Europe, Middle East and Africa
281.8

 
256.8

 
242.3

Other
115.1

 
124.3

 
80.3

 
$
3,162.5

 
$
3,215.6

 
$
3,221.6

Long-lived assets (2):
 
 
 
 
 
U.S.
$
734.3

 
$
770.7

 
 
Europe, Middle East and Africa (3)
169.9

 
146.7

 
 
Other
4.8

 
76.8

 
 
 
$
909.0

 
$
994.2

 
 
(1)
Net sales are attributed to regions based on the location of the entity that records the transaction, none of which relate to the country of Ireland.
(2)
Long-lived assets are primarily composed of property, plant and equipment, net.
(3)
Includes long-lived assets located in Ireland of $168.4 million and $145.2 million as of December 27, 2019 and December 28, 2018, respectively.

 [4],[5],[6]
[1]
Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.
[2]
Includes restructuring-related accelerated depreciation.
[3]
Amitiza net sales consist of both product and royalty net sales. Refer to Note 4 for further details on Amitiza's revenues.
[4]
Includes long-lived assets located in Ireland of $168.4 million and $145.2 million as of December 27, 2019 and December 28, 2018, respectively.
[5]
Long-lived assets are primarily composed of property, plant and equipment, net.
[6]
Net sales are attributed to regions based on the location of the entity that records the transaction, none of which relate to the country of Ireland.